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Systemic Isotretinoin Therapy Normalizes
Exaggerated TLR-2-Mediated Innate Immune
Responses in Acne Patients
Melanie C. Dispenza1, Ellen B. Wolpert1, Kathryn L. Gilliland1, Jenny P. Dai2, Zhaoyuan Cong1,
Amanda M. Nelson3 and Diane M. Thiboutot1
Retinoids are used in the treatment of inflammatory skin diseases and malignancies, but studies characterizing
the in vivo actions of these drugs in humans are lacking. Isotretinoin is a pro-drug for all-trans retinoic acid,
which can induce long-term remissions of acne; however, its complete mechanism of action is unknown. We
hypothesized that isotretinoin induces remission of acne by normalizing the innate immune response to the
commensal bacterium Propionibacterium acnes. Compared with normal subjects, peripheral blood monocytes
from acne patients expressed significantly higher levels of Toll-like receptor 2 (TLR-2) and exhibited significantly
greater induction of TLR-2 expression following P. acnes stimulation. Treatment of patients with isotretinoin
significantly decreased monocyte TLR-2 expression and subsequent inflammatory cytokine response to P. acnes
after 1 week of therapy. This effect was sustained 6 months following cessation of therapy, indicating that TLR-2
modulation may be involved in the durable therapeutic response to isotretinoin. This study demonstrates that
isotretinoin exerts immunomodulatory effects in patients and sheds light on a potential mechanism for its long-
term effects on acne. The modulation of TLR-2 expression on monocytes has important implications in other
inflammatory disorders characterized by TLR-2 dysregulation.
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INTRODUCTION
Acne is the most common inflammatory skin condition
affecting millions of individuals. Its pathogenesis involves
hormonally-induced production of sebum, altered keratiniza-
tion of the hair follicle, and an inflammatory immune
response to the Gram-positive Propionibacterium acnes
bacterium that resides within the lipid-rich follicle. However,
the specific trigger that initiates the development of acne is
unknown. Although acne responds to antibiotics, it is not
considered to be an infectious disease but may represent an
exaggerated immune response to the commensal P. acnes
bacteria. Although not everyone gets acne, nearly all humans
are colonized by P. acnes, and the density of P. acnes does
not correlate with the severity of inflammation (Leyden et al.,
1998). The immune responses of acne patients to P. acnes
may play a larger role in acne than the pathogenicity of
P. acnes itself (Sugisaki et al., 2009).
Systemic retinoids are used to treat severe acne, inflamma-
tory skin diseases, cutaneous T-cell lymphoma, neuroblasto-
ma, and acute promyelocytic leukemia. Retinoids inhibit
inflammatory T helper type 17 (Th17) T-cell responses,
promote regulatory T cell (Treg) responses, and regulate
expression of Toll-like receptors (TLRs) (Mucida et al., 2007;
Xiao et al., 2008). In vitro treatment of normal human
monocytes with all-trans retinoic acid (ATRA) downregulates
TLR-2 expression (Liu et al., 2005), but this effect has not been
examined in patients treated with systemic retinoids. Isotreti-
noin (13-cis retinoic acid; 13-cis RA) is the only drug capable
of inducing a long-term or permanent remission of acne;
however, the mechanisms leading to this durable response
are unknown. Given the role of TLR-2 in initiating immune
responses to P. acnes, we hypothesized that downregulation of
TLR-2 on monocytes and/or the induction of Treg responses
in vivomay represent mechanisms by which isotretinoin exerts
its long-term effects. In this study, we document the time
course of immunomodulation by isotretinoin in treated
patients. These findings are relevant not only to treatment of
acne, but also to disorders characterized by TLR-2 dysregula-
tion and other retinoid-responsive conditions.
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RESULTS
Acne patients who were scheduled by their dermatologist to
begin treatment with isotretinoin for severe acne were
recruited. Normal healthy volunteers without acne or prior
history of isotretinoin exposure served as controls. A total of
27 acne patients, 10 males and 17 females, with a mean
(±SEM) age of 17.9±1.4 years and 23 normal volunteers, 8
males and 15 females, with a mean (±SEM) age of 22.4±1.5
years were enrolled. Of the 27 acne patients treated with
isotretinoin, 10 completed the study through 20 weeks of
isotretinoin therapy, 8 of whom were reevaluated 6 months
after completing therapy. Of the remaining patients, one
discontinued isotretinoin at the direction of his dermatologist,
two discontinued because of medication costs, one withdrew
consent, and six were lost to follow-up between 8 and 20 weeks.
Acne lesion counts were performed at all visits to assess
treatment response (Supplementary Figure S1 online). As an
indicator of compliance, serum levels of isotretinoin and its
isomers ATRA and 9-cis RA were assessed (Supplementary
Figure S2 online). Levels were also measured in normal
volunteers for comparison. No differences in serum levels of
isotretinoin, ATRA, or 9-cis RA were found between acne
patients at baseline and normal volunteers.
Monocytes from acne patients express significantly greater
levels of TLR-2 and significantly lower levels of TLR-4 compared
with normal volunteers
Monocytes from acne patients secrete significantly higher
levels of cytokines when exposed to P. acnes compared
with monocytes from normal subjects (Sugisaki et al.,
2009). We sought to test the hypothesis that monocytes
from acne patients express higher levels of TLR-2 when
exposed to P. acnes, which may account for this obser-
vation. At baseline, unstimulated monocytes from acne
patients expressed higher levels of TLR-2 than normal
volunteers (P¼0.036; Figure 1). Treatment with P. acnes
sonicate induced TLR-2 expression in monocytes from
both patients and volunteers, but expression was significantly
greater in monocytes from acne patients (P¼0.041). In
contrast, P. acnes–stimulated monocytes from acne patients at
baseline expressed significantly lower levels of TLR-4
compared with normal volunteers (P¼ 0.016; Figure 2).
Isotretinoin downregulates cell surface expression of TLR-2,
but not TLR-4, on monocytes from patients in vivo
To assess the ability of systemic isotretinoin therapy to
modulate TLR expression in vivo, peripheral blood samples
were taken from acne patients before and during isotretinoin
therapy for acne (Figure 1). Compared with baseline,
unstimulated monocytes from patients treated with isotreti-
noin had significantly decreased TLR-2 expression as early
as 1 week of treatment (Po0.001), which continued to
decrease at each time point examined (4 weeks, P¼0.004;
8 weeks, P¼0.001; 20 weeks, P¼0.040; Figure 1). Similarly,
decreased TLR-2 expression was noted when monocytes
from patients treated with isotretinoin were stimulated
with P. acnes sonicate (1 week, P¼ 0.004; 4 weeks,
P¼0.017; 8 weeks, P¼ 0.001; 20 weeks, P¼ 0.006;
Figure 1) or whole heat-killed P. acnes (data not shown).
In comparison, isotretinoin therapy did not affect TLR-4
expression on monocytes from acne patients at any point
during therapy (Figure 2).
As the majority of patients treated with a full course of
isotretinoin (B20 weeks) have a permanent remission of their
acne (Liu et al., 2008a), we sought to test the hypothesis that
the dramatic reduction in monocyte TLR-2 expression persists
following cessation of isotretinoin therapy. To do this, we
modified our clinical protocol and were able to reexamine
8 of the 10 patients who completed 20 weeks of therapy.
At 6 months after stopping isotretinoin, the mean fluores-
cence intensity of TLR-2 in unstimulated and P. acnes-
stimulated monocytes was reduced by about 70% from
pretreatment levels. This was still significantly decreased
compared with baseline (P¼ 0.004 and 0.0004, respectively),
and not significantly different from normal volunteers
(Figure 1). Additionally, TLR-4 expression in monocytes from
acne patients at 6 months after treatment was no longer
significantly lower than normal volunteers.
Isotretinoin therapy decreases inflammatory cytokine
production by monocytes from patients in response to P. acnes
To determine if isotretinoin alters monocyte cytokine res-
ponse to P. acnes stimulation, supernatants from cultured
monocytes were assayed for inflammatory cytokines using
bead arrays. Before isotretinoin therapy, unstimulated mono-
cytes from acne patients secreted more tumor necrosis factor-
a than monocytes from normal volunteers, but because of
interpatient variability, did not differ in secretion of other
inflammatory cytokines (Figure 3). In response to stimulation
with P. acnes sonicate, monocytes from acne patients at
baseline secreted more IL-1b, IL-6, IL-10, and IL-12p70 than
monocytes from normal volunteers. Isotretinoin therapy
significantly decreased the secretion of IL-1b, IL-6, IL-10,
and IL-12p70 by monocytes from acne patients in response
to P. acnes compared with pretreatment levels. Cytokine
secretion decreased as early as 1 week after isotretinoin
therapy and continued to decrease through 20 weeks of
therapy. Additionally, this decrease was sustained at 6
months after the cessation of therapy. Pearson’s correlation
analysis showed high correlations between TLR-2 expression
and secretion of IL-1b (Po0.000), IL-6 (Po0.000), IL-8
(P¼0.001), and IL-10 (Po0.000), but not IL-12p70 (P40.1)
in P. acnes–stimulated monocytes from volunteers and acne
patients during isotretinoin therapy. Similar results were
observed in monocytes treated with whole heat-killed
P. acnes (data not shown).
Isotretinoin therapy does not alter the proportion or function
of circulating Tregs
Tregs suppress inflammatory responses and are of great
interest as potential therapies for autoimmune and chronic
inflammatory diseases. Because the peripheral conversion of
undifferentiated T cells into Tregs may involve ATRA (Mucida
et al., 2007; Xiao et al., 2008; Wang et al., 2009), we also
sought to test the hypothesis that isotretinoin might increase
the proportion of circulating Tregs in treated patients.
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Peripheral proportions of CD4þCD25þ Foxp3þ Tregs were
not significantly different in acne patients during isotretinoin
therapy compared with baseline (Supplementary Figure S3
online). Additionally, we found no differences between acne
patients and normal volunteers in peripheral proportions
of Tregs. To investigate whether in vivo priming with
isotretinoin renders peripheral naive T cells more likely to
differentiate into Tregs upon activation, lymphocytes were
also stimulated for 5 days with anti-CD3 and anti-CD28
antibodies, P. acnes sonicate, or vehicle. The T cells of
acne patients during isotretinoin therapy were not more
likely to differentiate into Tregs upon stimulation compared
with baseline (data not shown). These data suggest that
systemic isotretinoin therapy does not necessarily impart
Treg-differentiating signals on naive T cells in the periphery
in vivo.
To determine if isotretinoin affects peripheral Treg-
suppressive function, peripheral lymphocyte proliferation
was measured using 3H-thymidine incorporation assays.
Isotretinoin therapy did not affect proliferation of lympho-
cytes from acne patients at either an unstimulated basal
level or in response to activation by anti-CD3/anti-CD28
antibodies or P. acnes sonicate (Figure 4). Interestingly, in
response to P. acnes antigen, acne patients had significantly
suppressed lymphocyte proliferation compared with normal
volunteers (P¼ 0.009). Taken together, these data suggest that
acne patients have a blunted lymphocyte proliferative
response to P. acnes and that treatment with isotretinoin
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Figure 1. Isotretinoin therapy downregulates surface expression of Toll-like receptor 2 (TLR-2) on the monocytes from patients in vivo. Peripheral
blood was taken from normal volunteers (n¼ 23) and acne patients (Pts) at baseline and at 1, 4, 8, and 20 weeks of isotretinoin therapy and 6 months
after cessation of therapy (n¼ 25, 19, 19, 17, 10, and 8, respectively). Isolated monocytes were treated with Propionibacterium acnes–treated sonicate or
no antigen (unstimulated) and analyzed by flow cytometry. (a) Contour plots of monocytes from one representative patient are shown. (b) Displayed is the mean
fluorescence intensity (MFI)±SEM of TLR-2 expression for patients at baseline versus volunteers as well as (c) TLR-2 levels of patients over the course of
isotretinoin therapy. *Po0.05, **Po0.01, and ***Po0.001.
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does not alter the proportion or function of circulating Tregs
in acne patients.
Acne patients have higher serum concentrations of IL-10, but
not inflammatory cytokines, compared with healthy volunteers
Aside from suppression by Tregs, lymphocyte proliferation
can also be inhibited by immunosuppressive cytokines such
as IL-10. Serum was collected from all subjects during the
study for assay of cytokine levels. At baseline, acne patients
had significantly higher levels of serum IL-10 compared
with normal volunteers (P¼0.002; Figure 5). Interestingly,
isotretinoin did not affect serum IL-10 levels at any time
point, and serum IL-10 remained elevated throughout
therapy. It must be noted that these levels are low and
their clinical significance is unknown. In contrast, acne
patients did not differ from normal volunteers in serum
concentrations of IL-1b, IL-6, IL-8, or IL-12p70, nor did
isotretinoin therapy significantly affect serum concentra-
tions of these cytokines.
Isotretinoin therapy does not affect cytokine secretion by
peripheral blood lymphocytes
Retinoid treatment of T cells can skew helper T-cell differen-
tiation and responses. To investigate the effects of systemic
isotretinoin therapy on the secretion of Th1-, Th2-, and
Th17-associated cytokines by peripheral lymphocytes,
media supernatants from P. acnes– and anti-CD3/anti-
CD28–stimulated lymphocytes were analyzed at 20 hours
and 5 days of treatment. Isotretinoin did not significantly
affect IL-2, IL-4, IL-5, IL-10, IL-17A, tumor necrosis factor-a,
or IFN-g secretion by lymphocytes in any treatment group
(data not shown), suggesting that peripheral T-cell differentia-
tion was unaffected. Additionally, we did not find any
difference in the proportions of Tregs, Th2, or Th17 cells as
assessed by flow cytometry of the lymphocytes from patients
(data not shown).
DISCUSSION
Disorders characterized by inflammation such as acne,
rosacea, psoriasis, psoriatic arthritis, and Behcet’s disease
have been linked to dysregulation of innate immune signaling
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Figure 3. Isotretinoin therapy decreases inflammatory cytokine production by the monocytes from acne patients in response to Propionibacterium acnes.
Media supernatants from treated monocytes were analyzed for inflammatory cytokine concentrations using bead arrays. Basal cytokine concentrations
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(Candia et al., 2007; Do et al., 2008; Yamasaki et al., 2011).
Acne, psoriasis, and rosacea are thought to represent
disorders of dysbiosis characterized by an imbalance of
microorganisms within the cutaneous microbiome that leads
to altered innate immune responses and noninfectious skin
inflammation (Gallo and Nakatsuji, 2011). Additionally,
patients with acne, psoriatic arthritis, and Behcet’s disease
have increased expression of TLR-2 on circulating mono-
cytes, implying that the dysregulation of innate immune
signaling extends beyond the skin (Candia et al., 2007;
Do et al., 2008; Fathy et al., 2009). The increased expression
of TLR-2 on the peripheral monocytes from acne patients
suggests that acne is one such disorder characterized by
dysregulation of innate immune signaling in response to
P. acnes.
The mechanism of action of isotretinoin in inducing long-
term remissions of acne is unknown. We sought to test the
hypothesis that the systemic administration of isotretinoin, a
pro-drug for ATRA, would ‘‘normalize’’ the innate immune
response to P. acnes in patients with severe acne. To our
knowledge, this study is the first to demonstrate a durable
downregulation of TLR-2 and downstream cytokines from
systemic administration of a retinoid. Treatment with oral
isotretinoin not only decreased TLR-2 expression beginning
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as early as 1 week after therapy, but also blunted the rise in
TLR-2 expression when monocytes were exposed to P. acnes.
Most interestingly, the suppression of TLR-2 expression
persisted at least 6 months following completion of therapy,
suggesting that this may play a role in the long-term remission
of acne following isotretinoin. We did not observe a signi-
ficant correlation between age and monocyte TLR-2 expres-
sion in either acne patients or normal volunteers within the
age range of this study, suggesting that the downregulation of
TLR-2 does not represent a physiologic mechanism for the
resolution of acne with age.
The mechanism by which retinoids affect TLR expression
is unknown. In vitro treatment of normal human monocytes
with ATRA downregulates TLR-2 mRNA (Liu et al., 2005),
suggesting that isotretinoin operates by a similar mechanism
in the monocytes from acne patients in vivo. Although
retinoic acid-responsive elements are notably absent from the
human TLR-2 gene promoter, it is possible that isotretinoin
may be acting through retinoid X receptor activation via 9-cis
RA. Retinoid X receptors dimerize with multiple different
nuclear receptors such as the vitamin D receptor. Activation
of vitamin D receptor can downregulate TLR-2 expression on
normal human monocytes and monocytes from Bechet’s
patients (Sadeghi et al., 2006; Do et al., 2008); however,
vitamin D did not affect TLR-2 expression in normal
monocytes in our system when incubated with either fetal
bovine serum or human serum (data not shown).
Our study also shows that systemic isotretinoin decreases
secretion of inflammatory cytokines by peripheral monocytes
from patients to ‘‘normal’’ levels for at least 6 months after the
cessation of therapy. These results are in accordance with
in vitro data on the effect of ATRA on monocyte cytokine
response to P. acnes (Liu et al., 2005). Although a minor point
of our study, it is interesting to note that the secretion of IL-10
was higher in the monocytes from acne patients at baseline
compared with those of healthy volunteers in response to
P. acnes. IL-10 is an anti-inflammatory cytokine that is
produced by multiple cell types including Tregs, Th2 cells,
and monocytes. Our findings differ from reports that
peripheral blood mononuclear cells (PBMCs) from acne
patients secrete less IL-10 in response to P. acnes than PBMCs
from healthy volunteers. These differences may be because of
the increased severity of acne in our patient population. The
inflammatory signature of acne lesions has been examined
(Kang et al., 2005; Trivedi et al., 2006a). Acne lesions express
46-fold higher IL-10 mRNA compared with normal skin
(Kang et al., 2005), and increased lesional expression of IL-10
has been recently reported in hidradenitis suppuritiva (Wolk
et al., 2011; van der Zee et al., 2011). This increase in IL-10 is
thought to represent a compensatory response to intense
inflammation (Kang et al., 2005). In terms of a putative role
of IL-10 in acne, IL-10 induces differentiation of monocytes
into CD209þ CD163þ macrophages (Montoya et al., 2009).
CD209þ macrophages have been shown to phagocytose
P. acnes, and CD163 is a scavenger receptor for heme (Liu
et al., 2008b). In a previous study of gene expression in acne
lesions, CD163 was significantly upregulated in acne lesions
compared with normal skin (Trivedi et al., 2006b). Interest-
ingly, ATRA has also been shown to induce differentiation of
CD209þ monocytes in vitro (Liu et al., 2008b). These data
would suggest a model wherein IL-10 may in part suppress
inflammation in acne lesions by inducing differentiation of
monocytes into macrophages that scavenge both P. acnes
and cellular debris, and isotretinoin may augment this
endogenous response. Although isotretinoin decreases IL-10
secretion in monocytes (most likely via TLR-2 downregula-
tion), it has no effect on the low serum levels of IL-10,
possibly representing the contributions of other cell types.
We also present evidence that oral retinoid therapy for
up to 20 weeks does not affect peripheral proportions
of Tregs. Although ATRA concentrations of 10 nM are
sufficient for promoting naive T-cell differentiation into Tregs
in vitro (Wang et al., 2009), the serum levels of ATRA
obtained with therapeutic administration of isotretinoin
(in the 200 nM range) had no effect on Tregs. This is
particularly relevant to the use of retinoids in chemotherapy
or chemoprevention where there is a delicate balance
between cytotoxicity and preservation of immune surveil-
lance. Indeed, in multiple cancers the numbers or activity
of Tregs are increased in the periphery and the tumor
microenvironment, and higher numbers of Tregs correlate
with a worse prognosis (Woo et al., 2001; Liyanage et al.,
2002; Sasada et al., 2003; Curiel et al., 2004; Motta et al.,
2005; Yokokawa et al., 2008).
In conclusion, our data suggest that isotretinoin induces
remission in acne in part by ‘‘normalizing’’ immune response
of acne patients to P. acnes through downregulation of TLR-2
expression on monocytes. These changes persist for at least
6 months after the cessation of therapy, suggesting that this
effect may represent a long-term action of isotretinoin. Future
studies could determine the duration of these effects as well
as the effects of isotretinoin on the inflammatory signature of
acne microenvironment. TLR-2 downregulation may not be
permanent, but may be maintained long enough to either
modulate the adaptive immune response or to merely keep
acne in remission until other age-related factors affecting the
skin microbiome or sebaceous gland subside.
MATERIALS AND METHODS
Human subjects
Human studies were conducted in accordance with the Declaration
of Helsinki Principles as approved by Penn State’s Institutional
Review Board. All subjects gave written, informed consent. Subjects
included males and females aged 12–40 years who were scheduled
to begin treatment with isotretinoin for their moderately severe or
severe acne. Patients were not using other acne medications during
their isotretinoin therapy. One patient was using topical tretinoin
cream at the 6-month post-isotretinoin visit that has not been shown
to alter serum retinoids more than dietary fluctuations (Buchan et al.,
1994). Facial acne was assessed by visual counting of the numbers
of inflammatory and noninflammatory lesions at each visit. A 30ml
peripheral blood sample was obtained before starting isotretinoin
therapy (baseline) and at 1, 4, 8, and 20 weeks after starting their
isotretinoin therapy (0.5–1mg kg–1 day–1) and, when possible,
6 months after the cessation of their isotretinoin therapy. Samples
were assessed for retinoid levels and isolation of PBMCs. A single
www.jidonline.org 2203
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30ml peripheral blood sample was obtained from healthy
volunteers aged 12–40 years for the same analyses. All blood
samples were drawn into sodium-heparin tubes (BD Biosciences,
San Diego, CA).
HPLC and mass spectrometry
Concentrations of the three RA isomers in the serum samples from
patients were assayed by HPLC and mass spectrometry. Revisions
were made to an established method of sample extraction (Qu et al.,
2007), and liquid chromatography conditions were modified from
the literature (Kane et al., 2005). Selective solid-phase extraction was
employed varying the wash to 3ml of 50% methanol and elution to
3ml of 90% acetonitrile. Run time for the liquid chromatography
protocol was reduced from 30 to 20minutes via gradient, internal
standard, and multiple reaction monitoring modifications. Analyst
software, version 1.5.1 (AB Sciex, Framingham, MA) was used to
calibrate curves for the internal standard (acitretin).
P. acnes cultures
Reinforced Clostridal Broth (Difco, Lawrence, KS) was inoculated
with P. acnes (ATCC strain 6919), overlaid with N2 gas, and
grown overnight at 37 1C in a shaker until bacteria reached their log
growth phase. Bacteria were then washed twice and resuspended in
sterile phosphate-buffered saline. Sonicates were made by sonicating
suspensions three times for 30 seconds each. The sonicates and the
whole heat-killed P. acnes were completely nonviable as tested by
plating on Brucella agar in described conditions. Weights were mea-
sured using wet conditions. All sonicate preparations were stored
at 20 1C until use.
Stimulation of monocytes and lymphocytes
All sample processing took place in a sterile tissue culture hood
under yellow light. Blood samples were processed using a Ficoll-
Paque PLUS (GE Healthcare, Piscataway, NJ) density gradient according
to the manufacturer’s guidelines. PBMCs were separated into
lymphocytes and monocytes using the standard adherence method
(Jones et al., 1989). Samples consistently achieved at least 95% purity
with minimal contamination by other cell types as assessed by flow
cytometry. Monocytes were treated with vehicle or 1mgml–1
P. acnes sonicate in RPMI/10% (v/v) patient serum/antibiotics
for 20 hours. Lymphocytes were treated with vehicle, 1 mgml–1 P.
acnes sonicate, or 1 mgml–1 anti-CD3 antibody plus 1 mgml–1 anti-
CD28 antibody for 20 hours or 5 days. No changes in PBMC
viability were observed because of isotretinoin therapy or in vitro
stimulation.
Flow cytometry
Anti-human fluorochrome-tagged antibodies were all purchased
from BD Biosciences. Single-cell suspensions of monocytes and
lymphocytes were incubated with the appropriate antibodies in
phosphate-buffered saline containing 0.1% (w/v) NaN3 and 2% (v/v)
fetal bovine serum. For intracellular staining for Foxp3 in lympho-
cytes, the Foxp3 Staining Buffer Set (eBiosciences, San Diego, CA)
was used according to the manufacturer’s directions. All samples
were analyzed using an LSR II flow cytometer with FACSDiva
Software (both from BD Biosciences) and FlowJo Flow Cytometry
Analysis Software (Tree Star, Ashland, OR). All samples were
normalized to corresponding negative controls.
Cytokine detection using bead arrays
Supernatants from treated monocytes and lymphocytes and patient
serum were assayed for cytokines using Cytometric Bead Array kits
(BD Biosciences) according to the manufacturer’s directions.
Samples were run on a LSR II flow cytometer using FACSDiva
Software and analyzed using FCAP Analysis Software (both from BD
Biosciences). The theoretical minimum limit of detection for each
cytokine in samples was 0.25–0.5 pgml–1.
Lymphocyte proliferation assays
Lymphocytes of patients were stimulated with anti-CD3 and anti-
CD28 antibodies or P. acnes sonicate in RPMI/10% (v/v) patient
serum/antibiotics as described above. Cells were plated in triplicate
for 4 days. For the last 4 hours of incubation, cells were pulsed with
1 mCi per well of tritiated thymidine (Perkin-Elmer, Waltham, MA).
At the end of the incubation, cells were collected and the degree of
3H-thymidine incorporation was determined by liquid scintillation
analysis.
Statistical analyses
For all assays, each patient served as his/her own control, with data
from each time point during isotretinoin treatment being compared
back with his/her own baseline value. All patient data were analyzed
using paired Student’s t-tests for comparison of patient data across
isotretinoin therapy, and unpaired t-tests for comparison between
patients and healthy volunteers.
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